Go Pro
OTCMKTS:SBLOF

Shin Nippon Biomedical Laboratories (SBLOF) Stock Price, News & Analysis

$7.00 0.00 (0.00%)
As of 08/7/2026

About Shin Nippon Biomedical Laboratories Stock (OTCMKTS:SBLOF)

Advanced

Key Stats

Today's Range
$7.00
$7.00
50-Day Range
$7.00
$9.16
52-Week Range
$7.00
$9.16
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Shin Nippon Biomedical Laboratories, Ltd. (OTCMKTS: SBLOF) is a Japan‐based contract research organization specializing in nonclinical safety assessment for the pharmaceutical, biotechnology and agrochemical industries. Established in 1978 and headquartered in Kagoshima, the company provides a range of preclinical testing services designed to support drug development from early discovery through regulatory submission. SBLOF is known for its adherence to Good Laboratory Practice (GLP) standards and its focus on high‐quality data generation and compliance.

The company’s core services include toxicology studies, pharmacokinetics and bioanalysis, safety pharmacology, pathology and genetic toxicology. Using both rodent and non‐rodent models, SBLOF conducts acute, subchronic and chronic toxicity evaluations, as well as specialized studies such as reproductive and developmental toxicity. In addition to in vivo testing, the firm offers in vitro assays, biomarker analysis and method development to support both small‐molecule and biologic drug candidates.

SBLOF operates multiple GLP-compliant laboratories in Japan, including sites in Kagoshima and Tsukuba, and maintains collaboration agreements with facilities in Asia and North America to serve a global client base. The company’s geographic footprint enables it to accommodate diverse client requirements, from local biotech firms seeking regional expertise to multinational corporations conducting cross‐border programs.

Over its four decades of operation, Shin Nippon Biomedical Laboratories has maintained a focus on regulatory alignment and scientific rigor, guided by an experienced executive team based in Japan. The company continues to invest in facility upgrades, staff training and method validation to meet evolving industry standards and support the advancement of novel therapeutics.

AI Generated. May Contain Errors.

Receive SBLOF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Shin Nippon Biomedical Laboratories and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SBLOF Stock News Headlines

Shin Nippon Biomedical 9-Mos Net Y2.27B Vs Net Y3.21B
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.tc pixel
See More Headlines

SBLOF Stock Analysis - Frequently Asked Questions

Shin Nippon Biomedical Laboratories' stock was trading at $10.03 at the beginning of the year. Since then, SBLOF shares have decreased by 30.2% and is now trading at $7.00.

Shares of SBLOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Life Sciences Tools & Services
Sub-Industry
Life Sciences Tools & Services
Current Symbol
OTCMKTS:SBLOF
CIK
N/A
Fax
N/A
Employees
1,344
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (OTCMKTS:SBLOF) was last updated on 8/8/2026 by MarketBeat.com Staff.
From Our Partners